Danaher’s $9.9B Masimo Deal Marks One of 2026’s Largest Medtech Buyouts
Danaher (NYSE: DHR | DHR Price Prediction) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share. The transaction, announced February 17, 2026, represents a nearly 40% premium…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Danaher (NYSE: DHR | DHR Price Prediction) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share. The transaction, announced February 17, 2026, represents a nearly 40% premium over Masimo’s closing price on Friday, February 13, 2026.
What Masimo Brings to the Table
Masimo specializes in pulse oximetry and patient monitoring technology, generating $2.18 billion in revenue over the trailing 12 months. The company reported $371.5 million in revenue for Q3 2025, with non-GAAP EPS of $1.32, up 38% year-over-year. Masimo recently streamlined operations by selling its Sound United consumer audio division, allowing management to refocus on core medical device business.
Strategic Fit for Danaher
This acquisition follows Danaher’s playbook of adding high-quality diagnostics and life sciences assets. With $24.57 billion in trailing revenue and $7.14 billion in EBITDA, Danaher has the financial capacity to absorb this deal, which represents approximately 6.8% of its $145.88 billion market cap. Management expects the transaction to be accretive to earnings, with significant synergies anticipated.
Market Reaction Tells the Story
Masimo shares jumped 30.27% over the past week to $174.69, approaching the deal price. Meanwhile, Danaher shares dropped 6.09% over the same period to $206.36, reflecting investor concerns about dilution and integration costs. The deal requires Masimo shareholder approval and regulatory clearance, with closing expected in the second half of 2026.
Danaher is expanding its medical device footprint with this acquisition. Masimo shareholders will receive $180 per share in cash, representing a nearly 40% premium over the February 13, 2026, closing price, pending deal approval and regulatory clearance.
Contact [email protected] for any questions or corrections.
Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.
Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community.
Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.
Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, moderating workshop sessions at regional conventions.
